Form 4: Zevra Therapeutics Director Granted Stock Options

Zevra Therapeutics, Inc. reports the grant of stock options to Director Alicia Secor as compensation for her board service.

Summary

• Alicia Secor, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options on June 4, 2026.
• The exercise price for these options is $11.17 per share, equivalent to the closing stock price on the grant date.
• These options are part of the compensation for Secor's service on the company's board of directors.
• The options vest over time, with full vesting occurring on the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately prior to a change in control of the company, provided Secor remains in service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine director compensation and does not provide new financial or strategic information.

Positives

• Director compensation aligns with company stock performance on the grant date.
• Incentive aligns director's interests with shareholders through stock options.
• Clear vesting schedule tied to continued service and potential change of control.

Negatives

• No financial performance metrics or results are disclosed in this filing.

Risks

• The value of the stock options is directly tied to the future performance of Zevra Therapeutics' stock price.
• If the company's stock price declines, the stock options may not hold significant value.
• Vesting is contingent on continued service, meaning departure from the board would forfeit unvested options.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. The future outlook for the stock options is dependent on the company's stock price performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain experienced leadership, aligning their incentives with shareholder value.

Comparison to Industry Standards

• The grant of 30,000 stock options to a director is within the typical range for companies of Zevra Therapeutics' size and industry.
• The exercise price being set at the closing market price on the date of grant is a standard practice for non-qualified stock options.
• Vesting schedules tied to continued service and change-in-control provisions are common benchmarks in director compensation policies across the industry.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Alicia Secor is a related party transaction, as it involves compensation for services rendered by a director.

Stakeholder Impact

• Shareholders: The issuance of stock options dilutes existing share ownership slightly, but also aligns director incentives with long-term shareholder value.
• Employees: No direct impact on employees is indicated in this filing.
• Management: Reinforces standard compensation practices for the board of directors.

Next Steps

• Alicia Secor may exercise her stock options according to the vesting schedule.
• The company's stock performance will determine the ultimate value of these options.

Key Dates

Keywords

stock options, director compensation, Zevra Therapeutics, ZVRA, SEC Form 4, insider trading, equity award, board of directors